To further evaluate the sensitivity of dasatinib, ALW-II-41-27 and regorafenib on ESCC cells by CCK8 assay, we found that the cell proliferate rates of KYSE30 and KYSE150 cells with PT expression upon the treatment of these inhibitors were similar to those of KYSE30 and KYSE150 cells without PT expression (Fig. S11A-B), suggesting that PLEKHA1-TACC2 didn’t affect the sensitivity on cell proliferation of these inhibitors. Here, TACC2 is linked to esophageal squamous cell carcinoma.